New Eczematous Eruption in Patients With Inflammatory Bowel Disease Who Stop Janus Kinase Inhibitors.

IF 7.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

American Journal of Gastroenterology Pub Date : 2025-08-22 DOI:10.14309/ajg.0000000000003742

Russell Yanofsky, Benjamin D McDonald, Newsha Nikzad, David Choi, Christopher R Shea, Angad A Chadha, David T Rubin

引用次数: 0

Abstract

Introduction: Janus kinase inhibitors (JAKi) are small-molecule therapies used in inflammatory bowel disease (IBD). We describe 8 patients with IBD who developed an eczematous eruption, presumed atopic dermatitis (AD), after stopping JAKi therapy.

Methods: This case series describes 8 patients with IBD who developed de novo AD after withdrawal of JAKi therapy.

Results: Median time to AD onset was 7 days (interquartile range 2-12). Two cases with biopsy-confirmed AD resolved after reinitiation of JAKi therapy and adjunct AD treatments.

Discussion: A subset of patients with IBD may have latent susceptibility to AD, unmasked by therapy cessation and potentially triggered by an immune rebound effect.

查看原文本刊更多论文

停用Janus激酶抑制剂后炎症性肠病患者的新湿疹爆发。

目的：Janus激酶抑制剂（JAKi）是用于炎症性肠病（IBD）的小分子疗法。我们描述了8例IBD患者，他们在停止JAKi治疗后出现湿疹性爆发，推定为特应性皮炎（AD）。方法：本病例系列描述了8例IBD患者在停止JAKi治疗后发生新发AD。结果：AD发病的中位时间为7天（IQR 2-12）。2例活检证实的AD在重新开始JAKi治疗和辅助AD治疗后消退。结论：一部分IBD患者可能对AD有潜在的易感性，这种易感性在治疗停止后被发现，并可能由免疫反弹效应触发。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Gastroenterology 医学-胃肠肝病学

CiteScore

11.40

自引率

5.10%

发文量

458

审稿时长

12 months

期刊介绍： Published on behalf of the American College of Gastroenterology (ACG), The American Journal of Gastroenterology (AJG) stands as the foremost clinical journal in the fields of gastroenterology and hepatology. AJG offers practical and professional support to clinicians addressing the most prevalent gastroenterological disorders in patients.